A comparison between intravenous and subcutmaneous immunogobulin.
Multifocal motor neuropathy (MMN) is a rare immune-mediated disease that presents with predominantly distal motor weakness in one or more limbs without sensory loss. Symptoms may give riseto functional impairment and consequently may affect quality of life. High-dose intravenous immunoglobulin's therapy (IVIg) is the current mainstay treatment, however, subcutaneous immunoglobuli(SCIg) is emerging as a viable alternative. The purpose of this study was to explore the patients' experience of SCIg and ascertain if those receiving it had an improved quality of life and treatmentsatisfaction compared to those receiving IVIg. Using a mixed method approach this paper will present its findings and key implications for clinical and research practice are considered. The results from this study suggest that home SCIg therapy may prove a more desirable treatment option than IVIg for a proportion of MMN patients.
School of Nursing, Midwifery and Social Work, College of Health and Social Care, University of Salford,
Mary E
ME
Braine
Amanda
A
Woodall
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007262:Infusions, Intravenous / Q000451:nursing; D055104:Infusions, Subcutaneous / Q000451:nursing; D008297:Male; D008875:Middle Aged; D015404:Nursing Methodology Research; D011115:Polyneuropathies / Q000188:drug therapy* / Q000451:nursing*; D011788:Quality of Life; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous